- Home
- ZION vs LEGN Comparison
ZION vs LEGN Comparison
Compare ZION & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZION | LEGN |
|---|---|---|
| Founded | 1873 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZION | LEGN |
|---|---|---|
| Price | $56.29 | $17.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 13 |
| Target Price | ★ $63.40 | $63.08 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 04-20-2026 | 03-10-2026 |
| Dividend Yield | ★ 3.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.39 | $43.65 |
| Revenue Next Year | $4.65 | $32.75 |
| P/E Ratio | $10.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.32 | $16.24 |
| 52 Week High | $66.18 | $45.30 |
Technical Indicators
Market Signals| Indicator | ZION | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 37.53 |
| Support Level | $54.97 | $16.24 |
| Resistance Level | $58.63 | $20.39 |
| Average True Range (ATR) | 1.49 | 0.78 |
| MACD | 0.15 | -0.17 |
| Stochastic Oscillator | 68.55 | 3.64 |
Price Performance
Historical ComparisonAbout ZION Zions Bancorporation N.A.
Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.